DevvStream

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 987.60
7.03 0.72
145,291
108.37M
US$ 107.030B
US$ 166.87
2.86 1.74
4.13M
383.24M
US$ 63.950B
US$ 96.34
-2.66 -2.69
1.01M
240.99M
US$ 23.220B
US$ 10.94
0.00 0.00
2.21M
805.85M
US$ 8.810B
US$ 27.82
0.06 0.22
528,885
187.13M
US$ 5.210B
US$ 163.00
-0.62 -0.38
83,240
28.56M
US$ 4.660B
US$ 67.64
0.96 1.44
150,236
59.12M
US$ 4.000B
US$ 60.25
16.18 36.71
6.14M
58.69M
US$ 3.540B
US$ 51.83
1.20 2.37
248,254
53.29M
US$ 2.760B
US$ 16.61
0.08 0.48
215,812
160.84M
US$ 2.670B
US$ 9.10
0.07 0.78
2.71M
230.27M
US$ 2.100B
US$ 34.22
-0.02 -0.06
271,760
61.36M
US$ 2.100B
US$ 37.16
0.08 0.22
501,376
54.70M
US$ 2.030B
US$ 8.02
0.04 0.50
444,825
221.50M
US$ 1.780B
US$ 17.16
-0.15 -0.87
220,468
93.40M
US$ 1.600B
US$ 4.66
-0.47 -9.09
1.10M
293.35M
US$ 1.370B
US$ 45.00
-0.57 -1.25
48,830
29.79M
US$ 1.340B
US$ 2.34
0.00 0.00
0
487.70M
US$ 1.140B
US$ 0.67
0.01 1.58
37.08M
1.71B
US$ 1.140B
US$ 3.79
-0.06 -1.56
719,758
293.92M
US$ 1.110B
US$ 21.75
-0.05 -0.23
424,731
47.98M
US$ 1.040B
US$ 8.39
0.04 0.48
22,081
113.04M
US$ 948.410M
US$ 23.18
-0.30 -1.28
312,164
38.07M
US$ 882.270M
US$ 7.14
-0.07 -0.97
958,249
119.08M
US$ 850.230M
US$ 15.31
0.00 0.00
0
50.23M
US$ 769.020M
US$ 3.05
-0.03 -0.97
513,385
247.17M
US$ 753.870M
US$ 12.94
-0.14 -1.07
196,216
49.72M
US$ 643.130M
US$ 18.79
-0.15 -0.79
103,960
33.61M
US$ 631.530M
US$ 1.61
0.00 0.00
1.40M
361.49M
US$ 582.000M
US$ 0.44
-0.01 -2.96
1.88M
1.21B
US$ 530.770M
US$ 7.51
0.05 0.67
174,855
68.38M
US$ 513.530M
US$ 45.20
3.82 9.23
131,009
10.69M
US$ 483.190M
US$ 4.22
-0.13 -2.99
675,734
113.08M
US$ 476.890M
US$ 14.33
0.09 0.63
17,468
32.42M
US$ 464.580M
US$ 6.38
-0.17 -2.60
210,822
70.47M
US$ 449.250M
US$ 2.13
-0.12 -5.33
4.31M
189.46M
US$ 403.550M
US$ 10.87
-0.26 -2.34
735,629
35.94M
US$ 390.670M
US$ 6.01
0.15 2.56
274,507
64.68M
US$ 388.730M
US$ 4.48
0.12 2.64
178,633
78.52M
US$ 351.380M
US$ 4.04
-0.13 -3.12
430,432
84.64M
US$ 341.950M
US$ 11.96
0.00 0.00
33,401
28.07M
US$ 335.720M
US$ 4.33
0.30 7.32
206,315
56.50M
US$ 244.360M
US$ 3.14
-0.12 -3.54
134,235
75.54M
US$ 236.820M
US$ 1.97
-0.05 -2.24
319,087
119.32M
US$ 234.460M
US$ 3.48
-0.03 -0.85
251,256
63.92M
US$ 222.440M
US$ 3.03
-0.02 -0.66
88,368
62.15M
US$ 188.310M
US$ 3.18
0.00 0.00
0
58.24M
US$ 185.200M
US$ 0.17
0.0011 0.65
600,084
1.02B
US$ 173.500M
US$ 0.17
-0.0027 -1.52
3.61M
979.95M
US$ 170.900M
US$ 2.34
0.11 4.78
454,263
69.00M
US$ 161.230M
US$ 4.91
0.00 0.00
0
25.13M
US$ 123.390M
US$ 4.58
-0.35 -7.10
50,621
26.30M
US$ 120.500M
US$ 1.77
-0.02 -0.84
686,976
68.01M
US$ 120.040M
US$ 2.15
0.03 1.42
400,398
55.16M
US$ 118.590M
US$ 2.72
0.00 0.00
0
42.81M
US$ 116.440M
US$ 2.60
-0.19 -6.78
15,665
44.16M
US$ 114.850M
US$ 6.21
-0.47 -7.04
50,406
18.36M
US$ 114.020M
US$ 1.53
0.02 0.99
36,467
69.93M
US$ 106.640M
US$ 1.56
-0.06 -3.42
281,465
68.26M
US$ 106.140M
US$ 8.22
0.00 0.00
0
11.46M
US$ 94.200M
US$ 0.85
-0.19 -18.28
1.90M
96.55M
US$ 82.060M
US$ 7.27
0.18 2.54
84,605
11.17M
US$ 81.150M
US$ 1.14
-0.04 -3.39
185,543
70.92M
US$ 80.850M
US$ 0.53
-0.0005 -0.09
1,100
149.93M
US$ 79.840M
US$ 22.93
0.00 0.00
0
3.13M
US$ 71.770M
US$ 1.07
0.04 3.88
596,810
66.86M
US$ 71.540M
US$ 2.64
0.00 0.00
32,790
26.29M
US$ 69.410M
US$ 28.20
-0.70 -2.42
5,449
2.43M
US$ 68.530M
US$ 5.00
0.00 0.00
0
13.01M
US$ 65.050M
US$ 1.57
-0.05 -2.80
128,882
41.45M
US$ 64.870M
US$ 1.30
0.02 1.56
118,800
48.26M
US$ 62.740M
US$ 2.21
0.09 4.27
44,101
26.41M
US$ 58.380M
US$ 1.93
0.23 13.53
230,035
29.24M
US$ 56.430M
US$ 1.68
-0.05 -2.89
55,813
33.42M
US$ 56.150M
US$ 2.12
-0.11 -4.73
4,988
25.93M
US$ 54.840M
US$ 3.12
0.24 8.33
100,999
15.80M
US$ 49.300M
US$ 12.01
0.00 0.00
0
4.05M
US$ 48.640M
US$ 1.84
0.02 1.10
122,570
24.55M
US$ 45.170M
US$ 2.46
0.01 0.41
41,159
18.05M
US$ 44.400M
US$ 1.00
-0.04 -3.83
101,258
44.12M
US$ 44.120M
US$ 2.64
-0.06 -2.15
17,503
15.87M
US$ 41.930M
US$ 1.39
-0.03 -2.11
140,750
29.65M
US$ 41.210M
US$ 0.90
0.00 0.00
0
45.44M
US$ 41.090M
US$ 0.85
-0.02 -2.31
87,169
43.22M
US$ 36.730M
US$ 1.21
0.00 0.00
0
27.58M
US$ 33.370M
US$ 1.30
-0.05 -3.70
44,879
23.95M
US$ 31.140M
US$ 1.63
-0.05 -2.97
5,122
18.96M
US$ 30.900M
US$ 2.64
0.18 7.50
94,935
11.51M
US$ 30.440M
US$ 0.79
-0.36 -31.30
546,406
38.13M
US$ 30.120M
US$ 1.00
0.00 0.00
0
30.11M
US$ 30.110M
US$ 5.53
-0.64 -10.37
1,637
5.39M
US$ 29.830M
US$ 1.21
0.05 4.67
9,181
24.46M
US$ 29.700M
US$ 1.11
0.0007 0.06
28,972
26.32M
US$ 29.230M
US$ 0.38
0.01 3.51
41,031
74.07M
US$ 28.370M
US$ 3.05
0.00 0.00
92,161
9.06M
US$ 27.630M
US$ 0.37
-0.01 -2.65
576,018
74.42M
US$ 27.390M
US$ 2.96
-0.21 -6.62
7,715
8.31M
US$ 24.600M
US$ 1.43
0.00 0.00
1.91M
15.98M
US$ 22.850M
US$ 0.61
0.11 22.09
759,884
35.88M
US$ 21.770M
US$ 0.78
-0.68 -46.55
1.29M
25.08M
US$ 19.440M
US$ 0.05
0.00 0.00
0
369.39M
US$ 18.470M
US$ 0.45
0.00 0.00
0
40.60M
US$ 18.360M
US$ 3.20
0.02 0.63
22,315
5.57M
US$ 17.820M
US$ 0.61
-0.01 -1.76
100,157
27.11M
US$ 16.640M
US$ 0.10
0.00 0.00
0
169.73M
US$ 16.560M
US$ 0.17
-0.002 -1.15
2.55M
95.54M
US$ 16.480M
US$ 0.04
0.002 5.56
113,227
399.68M
US$ 15.190M
US$ 0.70
0.00 0.00
77,085
21.59M
US$ 15.110M
US$ 0.33
-0.02 -5.98
73,500
45.76M
US$ 15.100M
US$ 0.41
0.00 0.00
0
36.03M
US$ 14.900M
US$ 0.46
0.004 0.88
98,180
31.87M
US$ 14.630M
US$ 0.36
0.0003 0.08
156,028
40.43M
US$ 14.510M
US$ 1.53
0.08 5.52
45,622
9.40M
US$ 14.380M
US$ 0.53
-0.0028 -0.53
53,816
26.26M
US$ 13.920M
US$ 4.32
-0.15 -3.36
13,826
3.22M
US$ 13.890M
US$ 2.21
-0.06 -2.64
9,500
5.85M
US$ 12.930M
US$ 0.86
0.02 2.31
12,086
14.22M
US$ 12.210M
US$ 2.08
0.09 4.76
5,904
5.41M
US$ 11.280M
US$ 0.16
0.00 0.00
0
69.64M
US$ 10.930M
US$ 1.70
0.31 22.29
2.06M
6.11M
US$ 10.390M
US$ 0.27
0.01 4.56
529,728
37.12M
US$ 10.130M
US$ 0.13
0.00 0.00
0
71.31M
US$ 9.280M
US$ 2.43
-0.07 -2.80
8,824
3.65M
US$ 8.870M
US$ 1.80
-0.02 -1.18
46,382
4.70M
US$ 8.450M
US$ 2.60
0.00 0.00
8,095
2.90M
US$ 7.540M
US$ 0.78
-0.03 -3.70
1,936
9.61M
US$ 7.500M
US$ 0.02
-0.0011 -5.12
23,963
358.45M
US$ 7.310M
US$ 0.07
0.00 0.00
0
98.66M
US$ 6.910M
US$ 0.40
-0.03 -6.19
14,172
16.89M
US$ 6.760M
US$ 6.40
-0.15 -2.29
2,337
1.04M
US$ 6.660M
US$ 5.25
0.00 0.00
0
1.22M
US$ 6.400M
US$ 0.05
0.00 0.00
0
138.81M
US$ 6.250M
US$ 0.16
0.001 0.64
5.42M
39.04M
US$ 6.170M
US$ 3.90
0.06 1.62
2,722
1.54M
US$ 6.000M
US$ 2.00
0.00 0.00
0
2.96M
US$ 5.920M
US$ 4.31
-0.09 -2.04
2,773
1.35M
US$ 5.820M
US$ 0.24
0.00 0.00
0
23.90M
US$ 5.760M
US$ 0.29
0.03 10.73
1.50M
19.78M
US$ 5.700M
US$ 0.06
0.00 0.00
0
96.42M
US$ 5.420M
US$ 0.90
0.11 13.95
550
5.97M
US$ 5.370M
US$ 1.10
-0.02 -1.79
73,089
4.84M
US$ 5.320M
US$ 0.04
0.00 0.00
0
122.72M
US$ 4.910M
US$ 0.28
-0.05 -14.32
2.73M
17.28M
US$ 4.900M
US$ 4.75
-0.41 -7.95
45,617
937,562
US$ 4.450M
US$ 0.57
-0.02 -3.69
108,824
7.59M
US$ 4.300M
US$ 3.01
-0.11 -3.66
8,608
1.37M
US$ 4.130M
US$ 0.21
0.03 14.53
1.97M
19.26M
US$ 3.950M
US$ 0.04
0.0075 23.08
58,347
96.36M
US$ 3.850M
US$ 1.15
0.03 2.22
70,545
3.26M
US$ 3.750M
US$ 2.13
0.15 7.58
582,446
1.61M
US$ 3.430M
US$ 0.0099
0.0023 30.26
2,500
315.92M
US$ 3.130M
US$ 0.03
0.0006 2.38
14,000
121.27M
US$ 3.130M
US$ 1.31
-0.06 -4.28
81,549
2.08M
US$ 2.730M
US$ 0.22
0.0073 3.36
4.50M
11.67M
US$ 2.620M
US$ 0.02
0.00 0.00
0
164.72M
US$ 2.550M
US$ 0.12
-0.0031 -2.60
4,772
21.84M
US$ 2.540M
US$ 0.02
0.00 0.00
0
132.63M
US$ 2.350M
US$ 0.03
-0.0089 -22.82
200
73.20M
US$ 2.200M
US$ 0.86
0.03 3.25
21,739
2.36M
US$ 2.030M
US$ 0.27
-0.42 -61.50
20,819
7.47M
US$ 1.980M
US$ 0.01
0.0004 3.17
30,769
147.17M
US$ 1.910M
US$ 0.02
0.00 0.00
0
47.82M
US$ 1.190M
US$ 0.03
0.00 0.00
0
30.74M
US$ 899K
US$ 0.75
0.004 0.54
766,321
994,528
US$ 742K
US$ 0.0054
0.00 0.00
0
116.77M
US$ 631K
US$ 0.05
0.00 0.00
0
10.70M
US$ 535K
US$ 0.01
0.00 0.00
0
35.87M
US$ 427K
US$ 0.004
0.00 0.00
0
79.41M
US$ 318K
US$ 0.0002
0.00 0.00
0
119.08M
US$ 24K
US$ 0.0005
0.00 0.00
0
18.98M
US$ 9K
US$ 0.0001
0.00 0.00
0
36.50M
US$ 4K
US$ 0.00
0.00 0.00
0
103.47M
US$ -
US$ 0.0001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
129.97M
US$ -

BioTech Stock News


BriaCell Therapeutics Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases Median progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3 Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studi... Read more


BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage... Read more


Regeneron Pharmaceuticals: Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO

Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially first-in-class combination across a range of advanced solid tumors TARRYTOWN, N.Y., May 23, 2024... Read more


Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Prod

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea 18 million people in U.S. are living with a cancer diagnosis and more than 2 million people... Read more


Lexaria Bioscience Awards Contract For Third GLP-1 Human Pilot Study

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's human pilot study #3, (the "Study")... Read more


HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined positive score (CPS) of 20 or higher, data showed confirmed objective response rate (ORR) of 53%, complete response (CR)... Read more


Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity  Pharmacokinetic and safety profile validate conditionally active approach  Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET  BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery... Read more


Ontrak Launches Groundbreaking Mental Health Digital Twin Technology, Revolutionizing Precision Mental Healthcare Delivery

MIAMI / May 23, 2024 / Business Wire / Ontrak Inc (NASDAQ: OTRK), a leading AI-powered and technology-enabled healthcare company, today announced the launch of its pioneering Mental Health Digital Twin (MHDT) technology. This innovative advancement in mental health care delivery seamlessly fuses human empathy with data-driven insights to provide personalized, precise, and effective care for individuals... Read more


Theriva Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead clinical candidate VCN-01 in combination with gemcitabine... Read more


AbbVie Completes Acquisition of Landos Biopharma

Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos... Read more


Zomedica Publishes White Paper Highlighting Expanded Market Opportunities for PulseVet Therapy

Data supports expanding use of PulseVet Shock Wave therapy to treat equine EIPH and equine asthma ANN ARBOR, MI / ACCESSWIRE / May 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, recently released a white paper showcasing the effectiveness of... Read more


Esperion Therapeutics: First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat...

NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Levels  This Makes Bempedoic Acid the First and Only LDL-C Lowering Treatment Indicated for Primary and Secondary... Read more


Bionano Genomics Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy

Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational... Read more


Lexaria Biosciences Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

KELOWNA, BC / ACCESSWIRE / May 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces two important new patent awards. The Company has received a new granted patent in Lexaria's patent family #21: Compositions and Methods for Treating Hypertension. This is the Company's third granted US patent in this... Read more


Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

ta presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable... Read more


Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials Primary physician research found high level of interest in Tonmya as a potential new treatment option for fibromyalgia Significant dissatisfaction reported with drugs currently approved by FDA for the treatment of... Read more


Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents LOS ALTOS, Calif. / May 21, 2024 / Business Wire / RenovoRx, Inc. (“RenovoRx” or the... Read more


LAVA Therapeutics Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND submission Strong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands... Read more


Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $7,541,046 for... Read more


Regeneron Pharmaceuticals: Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy... Read more


Esperion Therapeutics: Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted... Read more


eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with... Read more


Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate

NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class... Read more


Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid... Read more


Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the... Read more


Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

New production process will be developed based on Pluri’s proprietary 3D cell expansion technology Human breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adults Global elderly nutrition market is valued at $25.2 billion, estimated to reach $39.7 billion in less than 10 years HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology... Read more


Healthy Extracts Reports First Quarter 2024 Financial Results

Net Revenue up 12% with Strong Subscription-Based Revenue Growth LAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / Healthy Extracts Inc. (OTCQB:HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the quarter ended March 31,... Read more


Dosing Begins in Lexaria Bioscience Comprehensive GLP-1 Animal Study

Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? KELOWNA, BC / ACCESSWIRE / May 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing has begun in the 12-week animal study... Read more


Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023. Key financial highlights for the fourth quarter included the following: Net revenue in... Read more


StageZero Life Sciences Announces Q1 2024 Financial Results and Operational Update

TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS